Denis Corin, CEO of Q BioMed, talks about the future plans for the company which includes a new drug application.
Q BioMed was formulated as an acceleration company to go and source innovative undervalued biotechnology assets in the pharmaceutical space. Bring those in-house incubate them and accelerate their development. We’ve only really been around for two years and we’ve now got four products in our pipeline so developing all of those at full steam is going to keep us very busy. The first product, the radiopharmaceutical for the treatment of metastatic cancer, is essentially a commercial product now FDA approved and we’re in the process of doing final production validation for that product. We’ll be probably filing two IMD’s one for the autism spectrum disorder the rare pediatric disease by the end of this year and fairly closely behind that I would expect the liver cancer drug indeed to be filed. Both of those going into the clinic hopefully in early 2018 and the glaucoma drug will also be moved through its pre IND clinical program and into the clinic hopefully or IND enabling studies early in 2019. So, a tremendous amount of development ahead some really great catalyst and we should have an NDA or a new drug application by the end of next year which would be phenomenal for a very young company. The idea behind this was to develop an incubator that would have consistent milestone turnover and consistent catalyst events happening throughout our development pipeline and give our shareholders something really interesting to look forward to on a continuous basis.
Q BioMed Inc. is a biomedical acceleration and development company. We are dedicated to acquiring and providing strategic resources and expansion capital to innovative healthcare companies that strive to provide much needed healthcare and related products to patients in need.
By partnering with exceptional entrepreneurs we aim to help to create market-leading products and companies in the biomedical and healthcare sector. As entrepreneurs and investors with operational and technical expertise we embrace a collaborative approach to capital formation and business development.
We have identified several targets that could provide a substantial pipeline of innovative and high value assets. Q intends to maximize risk-adjusted returns by focusing on clinical stage and innovative products where the technical, regulatory, and commercial risks have been mitigated or major valuation inflections are imminent.
For more information on Q BioMed Inc. (QBIO) please fill out the form below.